The landscape of therapeutic interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor activators taking center stage. Initially, drugs like Reta, demonstrating impressive glucose control https://theresaxobe481194.jaiblogs.com/65896177/glp-3-receptor-agonists-reta-trizepatide-and-beyond